CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 20 enrolled
Drug / intervention
Xeris glucagon +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02018627
NCT02018627Phase 3Completed
CompareCT.gov

Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon

Steven J. Russell, MD, PhD·interventional·Posted Dec 23, 2013·Updated Oct 8, 2019

In Brief

A Phase 3 clinical trial evaluating Xeris glucagon and Lilly glucagon for Type 1 Diabetes. Completed, enrolled 20 participants across 1 site.

Detailed Summary

This study will test the hypothesis that micro-doses of Xerisol Glucagon (Xeris Pharmaceuticals) will be non-inferior by pharmacokinetic and pharmacodynamic criteria vs. micro-doses of Glucagon for Injection (Eli Lilly).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 23, 2013
Enrollment StartApr 1, 2014
Primary CompletionAug 2, 2018
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 12.5 years ago

Interventions

Xeris glucagondrug

The subject is given an injection of xeris glucagon

Lilly glucagondrug

The subject is given an injection of lilly glucagon